Literature DB >> 85056

Clinical characteristics of imipramine-induced orthostatic hypotension.

A H Glassman, J T Bigger, E V Giardina, S J Kantor, J M Perel, M Davies.   

Abstract

The effects of imipramine hydrochloride on blood-pressure were examined in a prospective and a retrospective study. In a prospective study of 44 depressed patients given imipramine in doses to achieve antidepressant plasma-concentrations there was no effect of the drug on lying blood-pressure. When patients then stood up, the drug produced an average fall in systolic pressure of 26 mm Hg (t = 13.6, P less than 0.001) that was consistent over the four weeks of observation. Contrary to expectation, this fall was independent of patients' age, pre-existing heart-disease, or plasma-level of the drug. The best predictor of orthostatic hypotension during treatment was the degree of orthostatic drop in pressure before treatment (r = 0.695, P less than 0.001). In order to establish the clinical significance of this orthostatic drop in pressure, a retrospective study of 148 depressed patients treated with imipramine was conducted. These 148 patients, average age 59 years, received an average dose of 225 mg of imipramine. Almost 20% of them had symptoms usually associated with orthostatic hypotension that were severe enough to interfere with their treatment: over 4% sustained physical injuries. In our experience orthostatic hypotension is the commonest serious cardiovascular side-effect of imipramine.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 85056     DOI: 10.1016/s0140-6736(79)90824-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  26 in total

Review 1.  Serotonin and blood pressure regulation.

Authors:  Stephanie W Watts; Shaun F Morrison; Robert Patrick Davis; Susan M Barman
Journal:  Pharmacol Rev       Date:  2012-03-08       Impact factor: 25.468

Review 2.  The safety of antidepressants.

Authors:  F de Jonghe; J A Swinkels
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 3.  Should selective serotonin reuptake inhibitors be prescribed to all patients with ischemic heart disease?

Authors:  Wei Jiang; Ranga R Krishnan
Journal:  Curr Psychiatry Rep       Date:  2004-06       Impact factor: 5.285

4.  Identifying and managing depression in the medical patient.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

Review 5.  Depression and ischemic heart disease: overview of the evidence and treatment implications.

Authors:  Wei Jiang; James A Blumenthal
Journal:  Curr Psychiatry Rep       Date:  2003-05       Impact factor: 5.285

Review 6.  Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 2: Cost-effectiveness analyses.

Authors:  J A Henry; C A Rivas
Journal:  Pharmacoeconomics       Date:  1997-06       Impact factor: 4.981

7.  An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies.

Authors:  Joachim Wernicke; Alberto Lledó; Joel Raskin; Daniel K Kajdasz; Fujun Wang
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 8.  Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?

Authors:  Pal Pacher; Valeria Kecskemeti
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

9.  Tricyclic antidepressant poisoning. Management of arrhythmias.

Authors:  P R Pentel; N L Benowitz
Journal:  Med Toxicol       Date:  1986 Mar-Apr

Review 10.  Depression and its treatment in cardiac patients.

Authors:  F Fernandez
Journal:  Tex Heart Inst J       Date:  1993
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.